2,800m2 facility will act as EMMAC’s import
and export hub with analytical, manufacturing, packaging and labelling
capabilities
LONDON–(BUSINESS WIRE)–EMMAC Life Sciences Ltd (“EMMAC” or the “Company”), the European
independent medical cannabis company, is pleased to announce that
construction has started on its planned EU-GMP facility in Malta. This
follows the preliminary approval from Malta Enterprise, the Maltese
government’s agency focused on attracting inward investment and
supporting enterprise in Malta, for the issuance of a full license
(covering cultivation / production / importation / exportation) under
the terms of the Production of Cannabis for Medicinal Use Act, 2018.
EMMAC has secured a long-term lease on the land approved by Malta
Enterprise and the Medicines Authority.
The 2,800m2 facility will be EMMAC’s importation,
exportation, testing and distribution hub for Europe and other
international markets.
Antonio Costanzo, CEO of EMMAC, commented: “We are excited to
begin construction on our facility in Malta. This hub will form a
critical part of the EMMAC network of licensed and certified facilities
across multiple European jurisdictions, to facilitate the distribution
of premium medical cannabis, the transfer of proprietary IP and
scientific research.”
-Ends-
About EMMAC
EMMAC Life Sciences Ltd is the European medical cannabis company,
working to join together the latest science and research with
cutting-edge cultivation, extraction and production. With supply and
distribution partnerships throughout Europe, EMMAC is working to
establish itself as both a thought leader in the industry, as well as
the European leader in the production and supply of medical cannabis,
hemp and other derivative products.
CAUTIONARY STATEMENT
All statements, other than statements of historical fact, in this news
release are forward-looking statements that involve various risks and
uncertainties, including, without limitation, statements regarding
potential values, the future plans and objectives of EMMAC Life Sciences
Ltd. There can be no assurance that such statements will prove to be
accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those
anticipated in such statements. These and all subsequent written and
oral forward-looking statements are based on the estimates and opinions
of management on the dates they are made and are expressly qualified in
their entirety by this notice. EMMAC Life Sciences Ltd assumes no
obligation to update forward-looking statements should circumstances or
management’s estimates or opinions change.
Contacts
Media enquiries:
Buchanan
Henry Harrison-Topham/
Jamie Hooper/ Ariadna Peretz
Tel: +44 (0) 20 7466 5000
[email protected]
www.buchanan.uk.com
For
scientific enquiries please contact [email protected]
For
general enquiries please contact [email protected]
or visit www.emmac.com
